On September 29, 2026 Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, reported that the Company has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, taking place October 5–7, 2026, in Mesa, Arizona. As part of this recognition, Chief Executive Officer Sanjeev Luther will deliver an Innovation Spotlight presentation on October 6, 2026, at 1:30 PM.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, Mr. Luther will showcase Ernexa’s differentiated off-the-shelf induced mesenchymal stem cell, or iMSC, platform and the Company’s progress toward becoming a clinical-stage oncology company. The presentation will focus on ERNA-101, Ernexa’s lead oncology cell therapy candidate, and the Company’s focused strategy to establish clinical proof of concept initially in platinum-resistant ovarian cancer, with the potential to expand ERNA-101 across the ovarian cancer treatment continuum and into additional solid tumor indications.

Mr. Luther will also highlight the differentiated characteristics of Ernexa’s synthetic iMSC platform, which is designed to provide a scalable, off-the-shelf treatment solution without the need for patient-specific cell harvesting, as well as recently announced preclinical findings supporting the therapeutic potential of ERNA-101, including:

Independent validation of ERNA-101 combination therapy: In a larger, statistically robust study conducted by an independent contract research organization, ERNA-101 in combination with anti-PD-1 therapy achieved complete tumor clearance and long-term survival in two-thirds of treated animals. No complete responses were observed in either monotherapy group or the untreated control group.
Complete tumor elimination and 100% long-term survival in an earlier ovarian cancer study: ERNA-101 in combination with PD-1 blockade achieved complete tumor clearance and 100% survival through the end of the study follow-up period, demonstrating the potential of ERNA-101 to enhance the activity of checkpoint inhibition in an immunologically cold tumor model.
Focused path toward clinical validation: Ernexa remains on track for a planned Investigational New Drug application submission for ERNA-101 in 2026. The Company believes establishing clinical proof of concept in ovarian cancer could provide a foundation for evaluating ERNA-101 across broader oncology indications.

Emerging Track Innovation Spotlight Presentation Details

Presenter: Sanjeev Luther, President & CEO
Company: Ernexa Therapeutics
Date: October 6, 2026
Time: 1:30 PM
Room: FLW Ballroom G

"We are honored that Ernexa has been selected for the Emerging Track at the 2026 Cell & Gene Meeting on the Mesa, and we look forward to sharing the progress we are making with ERNA-101," said Mr. Luther. "We believe this recognition reflects the potential of our differentiated approach to cell therapy as we prepare to transition ERNA-101 toward the clinic. Our strategy is focused on advancing one differentiated oncology candidate through a clear initial clinical pathway in platinum-resistant ovarian cancer, supported by a growing body of compelling preclinical evidence and independent validation of ERNA-101’s anti-tumor activity. As we advance toward planned clinical entry, we believe our synthetic, off-the-shelf iMSC platform provides a differentiated foundation to establish clinical proof of concept in ovarian cancer and potentially expand ERNA-101 into broader oncology indications. Most importantly, our focus remains on translating this strong preclinical foundation into a potential new treatment for patients who need better options."

Presented by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa brings together senior executives, investors, strategic partners and other decision-makers from across the cell and gene therapy industry. The 2026 program is expected to feature more than 100 company presentations and more than 5,000 partnering meetings focused on advancing scientific, clinical and commercial innovation across the sector.

For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com

(Press release, Ernexa Therapeutics, SEP 29, 2026, View Source [SID1234671172])